WP
TERN

Woodline Partners’s Terns Pharmaceuticals TERN Stock Holding History

Woodline Partners’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,377,283
Closed -$55.6M – 1149
2025
Q4 		$55.6M Buy
1,377,283
+1,085,228
+372% +$25.1M 0.22% 112
2025
Q3 		$2.19M Sell
292,055
-9,557
-3% -$61K 0.01% 722
2025
Q2 		$1.13M Hold
301,612
– – 0.01% 794
2025
Q1 		$832K Sell
301,612
-10,000
-3% -$40.8K 0.01% 784
2024
Q4 		$1.73M Buy
311,612
+10,388
+3% +$70.3K 0.01% 677
2024
Q3 		$2.51M Sell
301,224
-443,820
-60% -$3.65M 0.02% 453
2024
Q2 		$5.07M Buy
+745,044
New +$4.51M 0.05% 337

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Woodline Partners's TERN Position: Q1 2026 in Review

Woodline Partners sold out of Terns Pharmaceuticals (TERN) in Q1 2026, closing a stake of 1,377,283 shares — an estimated $55.6M sold.

Woodline Partners first reported a position in TERN in Q2 2024 and held it in 7 quarters. The position peaked at $55.6M in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Woodline Partners reported no remaining Terns Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Woodline Partners sold 1,377,283 Terns Pharmaceuticals shares in Q1 2026, an estimated $55.6M.
  • Woodline Partners first reported a position in Terns Pharmaceuticals in Q2 2024 and held it in 7 quarters.
  • Woodline Partners's Terns Pharmaceuticals position peaked at $55.6M in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.